From: Miglustat therapy in the French cohort of paediatric patients with Niemann-Pick disease type C
Patient | Age at onset of neurological manifestations | Age at start of miglustat therapy | Miglustat dose (mg/day) | Duration of miglustat therapy | Disease evolution* |
---|---|---|---|---|---|
Perinatal visceral | |||||
#1 | 2 months | 2 months | 50 | 2 months | NA† |
Early infantile | |||||
#2 | 5 months | 9 months | 100–150-100 | 22 months | Initially improved then worsened |
#3 | 6 months | 2 years 1 month | 200 | 18 months | Worsened |
#4 | 7 months | 2 years 3 months | 150–300–150 | 27 months | Worsened |
#5 | 9 months | 20 months | 200 | 13 months | Worsened† |
#6 | 9 months | 3 years 7 months | 200–300–150 | 18 months | Stabilized |
#7 | 10 months | 2 years 2 months | 200–150–200 | 12 months | Worsened |
#8 | 12 months | 2 years | 50–100 | 12 months | Worsened |
#9 | 12 months | 2 years | 100–200 | 8 months | Worsened |
Late infantile | |||||
#10 | 2 years | 4 years | 250 | 60 months | Stabilized |
#11 | 3 years | 8 years | 100–300 | 12 months | Improved |
#12 | 3 years | 12 years 7 months | 600–400 | 12 months | Worsened† |
#13 | 4 years 6 months | 8 years | 400 | 9 months | WorsenedŦ |
#14 | 5 years | 6 years | 150–250 | 36 months | Worsened transiently then stabilized |
#15 | 5 years | 7 years 9 months | 200–300 | 12 months | StabilizedŦ |
#16 | 5 years | 9 years 10 months | 400–200–400 | 9 months | Worsened transiently then improved |
#17 | 5 years | 10 years 3 months | 300 | 12 months | Improved |
Juvenile | |||||
#18 | 5–6 years | 7 years | 300 | 12 months | WorsenedŦ |
#19 | 5–6 years | 9 years 9 months | 400 | 7 months | Worsened then stable |
#20 | 6–8 years | 14 years 9 months | 600 | 30 months | Improved then stable |